Cigarette Smoke Exposure Reduces T2R-Driven Apoptosis in Head and Neck Squamous Cell Carcinoma
By
Kyle Polen
Sarah Sywanycz
Gavin Turner
Brianna L. Hill
Lily Huang
Zoey A. Miller
Casey Hanna
Lovely Raghav
Devraj Basu
Robert J. Lee
Ryan M. Carey
April 25, 2026
Clinical Scorecard: Cigarette Smoke Exposure Reduces T2R-Driven Apoptosis in Head and Neck Squamous Cell Carcinoma
At a Glance
Category Detail
Condition Head and Neck Squamous Cell Carcinoma (HNSCC) Key Mechanisms T2R-mediated apoptosis and its modulation by cigarette smoke exposure. Target Population Individuals diagnosed with HNSCC, particularly smokers. Care Setting Oncology and cancer treatment facilities.
Key Highlights
HNSCC is commonly linked to tobacco use, impacting disease progression. Continued smoking is associated with more aggressive disease and reduced survival. T2R activation in HNSCC correlates with improved patient survival. Cigarette smoke exposure may reduce T2R expression and function. Lidocaine, a T2R agonist, is being investigated in clinical trials for HNSCC. Guideline-Based Recommendations
Diagnosis
Diagnosis of HNSCC should consider tobacco use as a significant risk factor. Management
Standard treatments include surgery, radiation, and chemotherapy. Monitoring & Follow-up
Monitor for locoregional control and survival rates in patients continuing to smoke. Risks
Continued smoking increases the risk of aggressive disease and poor outcomes. Patient & Prescribing Data
Patients with HNSCC, particularly those with a history of smoking.
Investigate the role of T2R agonists like lidocaine in treatment protocols.
Clinical Best Practices
Encourage smoking cessation in patients diagnosed with HNSCC. Consider the impact of T2R signaling in treatment planning. Related Resources & Content
